Pelvic irradiation for stage II ovarian carcinoma.
Over a 20-year period, 34 patients with FIGO stage II ovarian carcinoma were treated with postoperative pelvic irradiation at the University of Michigan. Complications of radiation treatment were minimal. The overall actuarial disease-free 5-year survival was 53%. This was not significantly different for substages IIA, IIB, or IIC. Patients with well-differentiated tumors had a significantly better survival than patients with moderate or poorly differentiated tumors (P less than 0.05). The implications for managing stage II ovarian carcinoma are discussed.
Terada
K Y
KY
Department of Obstetrics and Gynecology, University of Michigan School of Medicine, Ann Arbor 48105.
Morley
G W
GW
Roberts
J A
JA
D000005:Abdomen / Q000528:radiation effects; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D010388:Pelvis / Q000528:radiation effects*; D011878:Radiotherapy / Q000009:adverse effects